Malignant melanoma, a prime example for poor response to various treatment modalities including chemotherapy, expresses bcl-2 in up to 90% of all cases. The anti-apoptosis gene bcl-2 belongs to a new category of oncogenes capable of regulating programed cell death. Induction of programed cell death has been proposed recently as the mechanism of action for a variety of chemotherapeutic agents. In the present study we could show a sequence specific downregulation of bcl-2 protein by phosphorothioate antisense oligonucleotides in human melanoma under in vitro conditions. In addition, we established a SCID-hu xenotransplantation melanoma model and evaluated the role of bcl-2 in the biology and chemoresistance of human melanoma in vivo by using the same antisense approach. We could demonstrate that antisense induced downregulation ofthe bcl-2 gene product of human melanoma grown in SCID mice results in a statistically significant decrease in tumor weight. Bcl-2 antisense treatment also reduced the chernoresislance of human melanoma rendering animals without detectable tumors after a combined bel-2 antisense-dacarbazine treatment. Reverse controls and mismatch phosphorothioate oligonucleotides had no such effects. These results strongly suggest an antisense mode of action, but this has yet to be confirmed at the RNA level. Our findings stress the notion that downregulation of bcl-2 in human melanoma may be a novel approach to overcome chemoresistance in this type of malignancy.
Read full abstract